Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of Anti-FLT3 CAR-T (TAA05) in Relapsed/Refractory AML
NCT05445011Phase 1Recruiting
- Start
- Jun 2022
- Primary completion
- Jun 2025
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TAA05 in acute myeloid leukemia (AML). Primary endpoint: Maximal Tolerable Dose at 2 years. Started Jun 2022; status: recruiting.
02
Drugs
TAA05
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05445011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05445011.